Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay 1 Jacques Cadranel 2, 3, 4 Amélie Lusque 5 Nicolas Meyer 6 Valérie Gounaut 7 Denis Moro-Sibilot 8 Jean-Marie Michot 9, 10 Judith Raimbourg 11, 12 Nicolas Girard 13 Florian Guisier 14, 15 David Planchard Anne-Cécile Metivier 16 Pascale Tomasini 17 Eric Dansin 18 Maurice Pérol 19 Marion Campana 20 Oliver Gautschi 21 Martin Früh 22 Jean-David Fumet 23 Clarisse Audigier-Valette 24 Sébastien Couraud 25, 26 Stéphane Dalle 27, 28 Marie-Thérèse Leccia 29 Marion Jaffro 30 Samia Collot 30 Gregoire Prevot 1 Julie Milia 1 Julien Mazières 1, *
* Corresponding author
12 CRCNA / Equipe 9 - Apoptose et Progression tumorale
INSERM - Institut National de la Santé et de la Recherche Médicale : U892, IRS-UN - Institut de Recherche en Santé de l'Université de Nantes
Abstract : Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially severe event.Between December 2015 and April 2016, we conducted a retrospective study in centres experienced in ICI use. We report the main features of ICI-ILD with a focus on clinical presentation, radiological patterns and therapeutic strategies.We identified 64 (3.5%) out of 1826 cancer patients with ICI-ILD. Patients mainly received programmed cell death-1 inhibitors. ILD usually occurred in males, and former or current smokers, with a median age of 59 years. We observed 65.6% grade 2/3 severity, 9.4% grade 4 severity and 9.4% fatal ILD. The median (range) time from initiation of immunotherapy to ILD was 2.3 (0.2-27.4) months. Onset tended to occur earlier in lung cancer versus melanoma: median 2.1 and 5.2 months, respectively (p=0.02). Ground-glass opacities (81.3%) were the predominant lesions, followed by consolidations (53.1%). Organising pneumonia (23.4%) and hypersensitivity pneumonitis (15.6%) were the most common patterns. Overall survival at 6 months was 58.1% (95% CI 37.7-73.8%).ICI-ILD often occurs early and displays suggestive radiological features. As there is no clearly identified risk factor, oncologists need to diagnose and adequately treat this adverse event.
Document type :
Journal articles
Complete list of metadatas

Cited literature [41 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01819272
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, June 20, 2018 - 11:09:54 AM
Last modification on : Thursday, November 14, 2019 - 11:02:13 AM
Long-term archiving on : Monday, September 24, 2018 - 2:52:31 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

Myriam Delaunay, Jacques Cadranel, Amélie Lusque, Nicolas Meyer, Valérie Gounaut, et al.. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal, European Respiratory Society, 2017, 50 (5), ⟨10.1183/13993003.00050-2017⟩. ⟨inserm-01819272⟩

Share

Metrics

Record views

244